Business
Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce it has executed an exclusive global license agreement with Elanco Animal Health Incorporated (Elanco; NYSE: ELAN) and affiliates for Monepantel, the active pharmaceutical ingredient in NUZ-001, Neurizon's lead investigational therapy in development for Amyotrophic Lateral Sclerosis (ALS
About this update from Elanco Animal Health Incorporated
[{"type":"text","content":"Highlights:","length":11,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Neurizon® Therapeutics and Elanco Animal Health enter into an exclusive global licensing agreement ","length":103,"tagName":"p"}]},{"val":[{"type":"text","content":"Provides worldwide rights for Neurizon to utilise Elanco's intellectual property, providing exclusive access to an extensive package of non-clinical studies and manufacturing data and outlines key terms for a future supply agreement for GMP-compliant Monepantel","length":275,"tagName":"p"}]},{"val":[{"type":"text","content":"Provides a clear pathway for accelerated global commercialisation of NUZ-001[1] and significantly de-risks future global regulatory approval processes","length":165,"tagName":"p"}]},{"val":[{"type":"text","content":"The license agreement represents the first step in formalising Neurizon's relationship with Elanco, with the next step focused on finalising a supply agreement expected H2 CY 2025","length":193,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":736,"olType":false},{"type":"text","content":"MELBOURNE, Australia, July 2, 2025 /PRNewswire/ -- Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce it has executed an exclusive global license agreement with Elanco Animal Health Incorporated (Elanco; NYSE: ELAN) and affiliates for Monepantel, the active pharmaceutical ingredient in NUZ-001, Neurizon's lead investigational therapy in development for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases in humans.","length":643,"tagName":"p"},{"type":"image","alt":"Neurizon Therapeutics Master Logo (PRNewsfoto/Neurizon Therapeutics Limited)","displaySize":"","headline":null,"caption":"Neurizon Therapeutics Master Logo (PRNewsfoto/Neurizon Therapeutics Limited)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":113,"url":"https://media.zenfs.com/en/prnewswire.com/04d0d9d409913dfec3923dc98767d531"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/RsdVU5pKYuarm1ExFCC2.w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE5OTtjZj13ZWJw/https://media.zenfs....